ASH 2024: Kura Oncology CEO Troy Wilson highlights combination data in 1L AML for the menin inhibitor ziftomenib
He describes the data Kura has presented at ASH and where he believes it puts the company in the competive picture, including why 1L is so important and the potential addressable patient population. Plus his take on the sector, and the success at Avidity Biosciences, a company he co-founded.